Definium Therapeutics, Inc. filings document the regulatory record of a British Columbia clinical-stage biopharmaceutical company traded on Nasdaq as DFTX. Current reports on Form 8-K disclose financial results, corporate highlights, investor-presentation materials, and clinical and commercial updates for DT120 ODT in psychiatric indications.
Definitive proxy materials cover annual general and special meeting matters, including director elections, auditor appointment, compensation governance, and shareholder voting procedures. Other filings record board composition changes, non-employee director compensation, stock option awards, indemnity arrangements, and the company’s corporate identity following its former name, Mind Medicine (MindMed) Inc.
Definium Therapeutics, Inc. (DFTX) is the subject of a notice that shareholder Robert B. Barrow intends to sell 19,023 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $718,144.88 as of the planned sale date of September 3, 2026.
These shares are tied to Performance Stock Units acquired from the issuer as compensation for services rendered on September 3, 2026, and follow a prior sale of 29,208 shares for $1,230,533.04 during the past three months.
Definium Therapeutics, Inc. investor Commodore Capital and related filers report beneficial ownership of 2,410,000 Common Shares, including shares underlying a pre-funded warrant, as of June 30, 2026. This represents 1.8% of the outstanding Common Shares of Definium Therapeutics, Inc.
The position consists of 2,000,000 Common Shares and 410,000 Common Shares that each filer has the right to acquire through exercise of a pre-funded warrant. Voting and dispositive power over all 2,410,000 shares is reported on a shared basis, with no sole voting or dispositive power. The ownership percentage is based on 134,365,950 Common Shares outstanding as of June 30, 2026, plus the 410,000 shares issuable upon exercise of the pre-funded warrant.
Definium Therapeutics, Inc. has a significant shareholder, Driehaus Capital Management LLC (DCM), which reported ownership of 6,845,276 shares of Definium common stock on a Schedule 13G/A. This position represented 5.36% of the outstanding common stock as of June 30, 2026.
DCM stated that its percentage interest was 5.36% as of June 30, 2026, compared with 6.64% as of December 31, 2025. All reported shares are held in numerous client accounts managed by DCM on a fully discretionary basis. DCM reported shared voting power and shared dispositive power over 6,845,276 shares, with no sole voting or dispositive power. The issuer changed its name from Mind Medicine (MindMed), Inc. to Definium Therapeutics, Inc. on January 12, 2026.
Definium Therapeutics, Inc. reported that Chief Executive Officer Robert Barrow acquired 375,000 common shares as a grant/award at a price of $0.0000 per share. The award represents the second tranche of performance share units granted effective March 12, 2025, and remains subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Barrow directly holds 1,473,246 common shares.
Karlin Daniel reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Medical Officer Daniel Karlin received a grant of 100,000 Common Shares at a price of $0.00 per share. These shares represent the second tranche of performance share units originally granted effective March 12, 2025, and remain subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement. Following this award, Karlin directly holds 603,282 Common Shares.
Definium Therapeutics, Inc. reported that Chief Legal Officer Mark Sullivan acquired 62,500 common shares on August 12, 2026, at a stated price of $0.00 per share, increasing his direct holdings to 383,071 shares. According to the award terms, these shares represent the second tranche of performance share units granted effective March 12, 2025 and remain subject to vesting based on continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones.
Definium Therapeutics, Inc. reported that Chief Commercial Officer Matthew T. Wiley acquired 62,500 common shares as a grant/award. According to the award terms, these shares represent the second tranche of performance share units granted effective March 17, 2025 and remain subject to vesting based on continued employment through March 17, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Wiley holds 237,133 common shares directly.
Roberts Brandi reported acquisition or exercise transactions in this Form 4 filing.
Definium Therapeutics, Inc. reported that Chief Financial Officer Brandi Roberts received a grant of 62,500 Common Shares on August 12, 2026, at a stated price of $0.00 per share as a grant or award. After this award, Roberts directly holds 271,987 Common Shares. The shares represent the second tranche of performance share units originally granted effective June 2, 2025, and remain subject to vesting based on continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones.
Definium Therapeutics reported positive topline Phase 3 results from Voyage, a pivotal study of DT120 ODT 100 µg in adults with generalized anxiety disorder. The trial enrolled 214 participants randomized 1:1 to DT120 or placebo over a 12‑week double‑blind period.
Voyage met its primary endpoint, with a least‑squares mean change in Hamilton Anxiety Rating Scale (HAM‑A) score at Week 12 of -11.6 for DT120 vs -6.2 for placebo, a placebo‑adjusted difference of -5.4 points (p<0.0001, Cohen’s d=0.81). Efficacy appeared rapidly, with improvements seen as early as Day 2 and sustained through all post‑baseline timepoints. Key secondary endpoints, including change in Clinical Global Impression‑Severity (CGI‑S), were also highly statistically significant at multiple visits.
DT120 ODT was generally well tolerated. In Part A, adverse events were mostly mild to moderate, transient, and concentrated on the dosing day, with no serious adverse events reported in the DT120 arm and no suicidality signal or suicidal behavior identified. About 43% of DT120‑treated patients achieved ≥50% HAM‑A improvement at Week 12 versus 16% on placebo, and 14% vs 4% reached remission (HAM‑A ≤7. The company highlighted consistent large effect sizes across three late‑stage studies of DT120 and noted that a second GAD Phase 3 trial, Panorama, is expected to deliver topline results in September 2026.
Definium Therapeutics, Inc., a late-stage biopharma focused on psychedelic-derived therapies for psychiatric and neurological disorders, reported Q2 2026 research and development expenses of $48.7 million and general and administrative expenses of $26.4 million, leading to a loss from operations of $75.1 million and a net loss of $158.986 million. For the first six months, the net loss was $236.1 million.
Total assets rose to $1,112.9 million at June 30, 2026, including approximately $1.1 billion of cash, cash equivalents and investments, driven largely by an $805.0 million June 2026 equity offering that generated $757.9 million in net proceeds. Shareholders’ equity increased to $918.7 million, and management believes current resources fund operations into 2030.
The company is advancing DT120, an orally disintegrating lysergide tablet, in multiple Phase 3 programs in generalized anxiety disorder, major depressive disorder and planned PTSD studies, and DT402 in Phase 2a for autism spectrum disorder. The Phase 3 Emerge study in major depressive disorder met its primary and all key secondary endpoints, with DT120 showing an 8.1-point placebo-adjusted improvement on the MADRS score at Week 6 (p<0.0001) and a generally tolerable safety profile.